Teriflunomide

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1053 publications

Clinical Efficacy and Brain Volumetric Changes in Pediatric-Onset Multiple Sclerosis Under Teriflunomide Treatment.

Clinical Efficacy and Brain Volumetric Changes in Pediatric-Onset Multiple Sclerosis Under Teriflunomide Treatment.

Journal: Journal of child neurology

Published: July 28, 2026

Teriflunomide Slows Osteoarthritis Progression via Wnt/β-Catenin and NLRP3 Pyroptosis Pathways.

Teriflunomide Slows Osteoarthritis Progression via Wnt/β-Catenin and NLRP3 Pyroptosis Pathways.

Journal: Tissue engineering. Part A

Published: July 24, 2026

Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis.

Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis.

Journal: Clinical immunology (Orlando, Fla.)

Published: July 07, 2026

Cyanoacetylation of amines via a traceless cyanoacetyl radical: synthetic access to teriflunomide.

Cyanoacetylation of amines via a traceless cyanoacetyl radical: synthetic access to teriflunomide.

Journal: Chemical communications (Cambridge, England)

Published: July 07, 2026

Mining of ancestral lipases and enzymatic synthesis of amides

Mining of ancestral lipases and enzymatic synthesis of amides

Journal: Sheng wu gong cheng xue bao = Chinese journal of biotechnology

Published: June 25, 2026

Safety and efficacy of anti-CD20 monoclonal antibodies versus teriflunomide in relapsing multiple sclerosis: a systematic review and meta-analysis.

Safety and efficacy of anti-CD20 monoclonal antibodies versus teriflunomide in relapsing multiple sclerosis: a systematic review and meta-analysis.

Journal: Acta neurologica Belgica

Published: June 18, 2026

Fluorescence HPLC Analysis of Teriflunomide in Human Plasma Following Derivatization with 4-Chloro-7-Nitrobenzofurazan: Method Development and Application to a Prototype Pharmacokinetic Evaluation.

Fluorescence HPLC Analysis of Teriflunomide in Human Plasma Following Derivatization with 4-Chloro-7-Nitrobenzofurazan: Method Development and Application to a Prototype Pharmacokinetic Evaluation.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: May 23, 2026

Progression-related outcomes of teriflunomide in multiple sclerosis clinical trials.

Progression-related outcomes of teriflunomide in multiple sclerosis clinical trials.

Journal: Frontiers in neurology

Published: May 15, 2026

Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination.

Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination.

Journal: Inflammopharmacology

Published: May 13, 2026

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Journal: Neurology. Clinical practice

Published: May 11, 2026

Real-world pharmacovigilance analysis of the association between multiple sclerosis disease-modifying therapies and intervertebral disc herniation.

Real-world pharmacovigilance analysis of the association between multiple sclerosis disease-modifying therapies and intervertebral disc herniation.

Journal: Frontiers in pharmacology

Published: May 10, 2026

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Journal: Neurology

Published: May 05, 2026

Showing 1-12 of 1,053

Last Updated: 09/26/2026